- Home
- KINS vs KOD Comparison
KINS vs KOD Comparison
Compare KINS & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- KOD
- Stock Information
- Founded
- KINS 1886
- KOD 2009
- Country
- KINS United States
- KOD United States
- Employees
- KINS N/A
- KOD N/A
- Industry
- KINS Property-Casualty Insurers
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KINS Finance
- KOD Health Care
- Exchange
- KINS Nasdaq
- KOD Nasdaq
- Market Cap
- KINS 251.5M
- KOD 259.6M
- IPO Year
- KINS N/A
- KOD 2018
- Fundamental
- Price
- KINS $16.30
- KOD $3.40
- Analyst Decision
- KINS Strong Buy
- KOD Hold
- Analyst Count
- KINS 1
- KOD 3
- Target Price
- KINS $6.50
- KOD $9.00
- AVG Volume (30 Days)
- KINS 428.3K
- KOD 440.1K
- Earning Date
- KINS 05-08-2025
- KOD 05-14-2025
- Dividend Yield
- KINS N/A
- KOD N/A
- EPS Growth
- KINS 5417.04
- KOD N/A
- EPS
- KINS 1.60
- KOD N/A
- Revenue
- KINS $169,875,701.00
- KOD N/A
- Revenue This Year
- KINS $40.63
- KOD N/A
- Revenue Next Year
- KINS $6.92
- KOD N/A
- P/E Ratio
- KINS $10.21
- KOD N/A
- Revenue Growth
- KINS 18.52
- KOD N/A
- 52 Week Low
- KINS $4.55
- KOD $1.92
- 52 Week High
- KINS $22.40
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- KINS 45.69
- KOD 45.30
- Support Level
- KINS $15.63
- KOD $3.46
- Resistance Level
- KINS $17.54
- KOD $3.81
- Average True Range (ATR)
- KINS 1.09
- KOD 0.42
- MACD
- KINS -0.18
- KOD -0.07
- Stochastic Oscillator
- KINS 9.90
- KOD 34.50
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.